Crossbow Therapeutics Secures $77 Million in Series B Financing to Advance First-in-Class TCE Therapy CBX-250

▲May 14-15Shanghai BiopharmaceuticalsInnovators SummitScan to Register

Disclaimer: Due to limited proficiency, errors are inevitable, and some information may not be the most up-to-date. Comments pointing out any issues are welcome. This article is only an introduction to drugs related to healthcare.Non-therapeutic program recommendations (if applicable); This article does not constitute any investment advice.。

The proceeds of this offering will be used to complete the company's core pipeline.CBX-250Phase 1 Clinical Trial.

CBX-250ForFirst-in-class T Cell Engager (TCE) Therapy, specifically targeting the surface of myeloid cancer cellsPeptide-Human Leukocyte Antigen Complex (pHLA)。

Currently ongoingCROSSCHECK-001 Phase I Study`, aimed to evaluate`CBX-250Efficacy in patients with relapsed/refractory myeloid malignancies, covering indications includingAcute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Myelodysplastic Syndromes (MDS), and Chronic Myelomonocytic Leukemia (CMML). Preliminary clinical data from the trial is expected to be released inBy the end of 2026Publish.

Crossbow TherapeuticsBased on itsT-Bolt™Technology platform, develop a series of novel TCE therapies. This type of therapy adoptsT Cell Receptor Mimic Antibodies (TCR-mimetics), which can strongly target the pHLA antigen on the surface of cancer cells, theoretically covering almost all tumor protein targets, and is suitable for treating various malignant tumors.

References:

PharmaCircle Data;

Crossbow Therapeutics pharma.bcpmdata.com (formerly Pharma Intelligence Data);

http://www.marketscreener.com；

https://www.pharmiweb.com/press-release/2026-03-18/crossbow-therapeutics-raises-77-million-in-series-b-financing-to-advance-development-of-tcr-mimetic；

https://www.businesswire.com；

www1.hkexnews.hk/；

; etc.

---